Skip to content

Study on the Prognosis of Acute Ischemic Stroke Based on Copeptin-Klotho-FGF-23

Study on the Prognosis of Acute Ischemic Stroke Based on Copeptin-Klotho-FGF-23

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121469
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

Observation group:None

Sponsors

Affiliated Hospital of Beihua University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, gender not restricted; 2. Diagnosed with acute ischemic stroke according to the World Health Organization diagnostic criteria, presenting with acute focal neurological deficits, and confirmed by cranial MRI plain scan or diffusion-weighted imaging (DWI); 3. Able to complete baseline NIHSS scoring and 90-day mRS follow-up, with clear hospitalization records; 4. The patient or their legal representative signs a written informed consent form, demonstrates good compliance, and is willing to cooperate with the entire study and follow-up.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women; history of hemorrhagic stroke, transient ischemic attack, or stroke with significant residual effects (mRS score >2); 2. Presence of malignant tumors, severe hepatic or renal insufficiency, severe cardiopulmonary disease, hematologic disorders, autoimmune diseases, or systemic infections/fever; 3. History of surgery, trauma, or fracture within the past 2-3 months; 4. Refusal to participate in the study, inability to sign informed consent, or presence of communication difficulties making it impossible to cooperate with NIHSS assessment, mRS follow-up, or data collection.

Design outcomes

Primary

MeasureTime frame
Copeptin;Klotho;Fibroblast growth factor-23;

Countries

China

Contacts

Public ContactZiying Wang; Lingling Wang

Beihua University; Affiliated Hospital of Beihua University

79225834@163.com+86 159 4865 9339

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026